The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events
Rheumatic Disease Clinics of North America · 2024-05 · 50 (2) · 181-199
DOI: 10.1016/j.rdc.2024.01.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rheumatic Disease Clinics of North America, 2024-05. Verfasst von Alexandra Ladouceur und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, Jewish General Hospital and McGill University, 3755 Côte Ste-Catherine Road, Montreal, Quebec H3T 1…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Rheumatic Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 120 Literaturangaben. Gefördert von: National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Center for Research Resources.
Themen: Patientensicherheit
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have greatly improved survival of several cancers with historically very poor prognosis. ICIs act by stimulating the patient's own immune system to fight cancer. Simultaneously, this immune activation can lead to immune-related adverse events (irAEs), including rheumatic manifestations (Rh-irAEs). Rh-irAEs mimic primary rheumatic diseases including arthritis, polymyalgia rheumatica, myositis, vasculitis, sarcoidosis, and sicca. This article summarizes the latest evidence regarding the utility of laboratory investigations in Rh-irAEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Medicine, Jewish General Hospital and McGill University, 3755 Côte Ste-Catherine Road, Montreal, Quebec H3T 1E2, Canada.
- Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, VU University Medical Center (VUmc), De Boelelaan 1118, Amsterdam 1081 HZ, the Netherlands.
- Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, 60 Fenwood Road, Suite 6016U, Boston, MA 02115, USA.
- Division of Rheumatology, Department of Medicine, Jewish General Hospital and McGill University, Lady Davis Institute for Medical Research, 3755 Côte Ste-Catherine Road, Montreal, Quebec H3T 1E2, Canada.
- Arthritis Research Canada, Department of Medicine, University of British Columbia, Gordon & Leslie Diamond Health Care Centre, 2775 Laurel Street, Ste 8205B, Vancouver, British Columbia V5Z 1M9, Canada.
- Faculty of Medicine & Dentistry, Department of Medicine, University of Alberta, 8-130 Clinical Sciences Building, 11350 83 Avenue NW, Edmonton, Alberta T6G 2G3, Canada.
Förderung
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Center for Research Resources
Zitieren
APA
Ladouceur, A., Ezdoglian, A., Sparks, J. A., Hudson, M., Jamal, S., Clifford, A., Roberts, J., & Ye, C. (2024). The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events. Rheumatic Disease Clinics of North America, 50(2), 181-199. https://doi.org/10.1016/j.rdc.2024.01.003
Vancouver
Ladouceur A, Ezdoglian A, Sparks JA, Hudson M, Jamal S, Clifford A, et al. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events. Rheumatic Disease Clinics of North America. 2024;50(2):181-199. doi:10.1016/j.rdc.2024.01.003
BibTeX
@article{Ladouceur2024,
author = {Ladouceur, Alexandra and Ezdoglian, Aiarpi and Sparks, Jeffrey A and Hudson, Marie and Jamal, Shahin and Clifford, Alison and Roberts, Janet and Ye, Carrie},
title = {The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events},
journal = {Rheumatic Disease Clinics of North America},
year = {2024},
volume = {50},
number = {2},
pages = {181--199},
doi = {10.1016/j.rdc.2024.01.003}
}
EUVIMED